Covering the Full Spectrum of
Blood tumors pose a serious threat to human health, ranging from myeloma, non-Hodgkin’s lymphoma to leukemia.
InnoCare’s scientists have been making every effort to combat blood tumors by developing a variety of small molecule and large molecule drugs.
Focusing on Huge Unmet Needs
InnoCare has focused a lot of effort on diffuse large B-cell lymphoma (DLBCL), a particular area with huge unmet needs.
InnoCare leads the way with a robust pipeline targeting diffuse large B-cell lymphoma (DLBCL). Our diverse tool-kit including orelabrutinib,tafasitamab, ICP-B02 and ICP-490 offers a unique position to treat all stages of DLBCL patients. This comprehensive range ensures enhanced and varied treatment alternatives for this aggressive form of lymphoma.
BTK Inhibitor
Anti-CD19 Antibody
Molecular Glue
CD3xCD20 Bispecific
Reinforce Competitiveness
Our drug discovery team has been constantly exploring better technologies and achieving exceptional innovations in target discovery, compound screening, and the selection of drug candidates, enabling us to develop excellent drug molecules with high selectivity and safety.
BTK Inhibitor
Highly Selective, Covalent
Approved for Marketing
Gunagratinib (ICP-192)
pan-FGFR Inhibitor
Highly Selective, Covalent
Inhibiting FGFR Gene Mutation
Zurletrectinib (ICP-723)
pan-TRK Inhibitor
Reversible, Highly Selective
Inhibiting NTRK Gene Fusion
R&D Areas
Solid Tumors
Building a Competitive Drug Portfolio

We strive to expand the breadth of our pipeline, covering solid tumor diseases areas, through a combination of targeted therapy and with immune-oncology approaches. We believe the potential best-in-class molecules, Gunagratinib (ICP-192), Zurletrectinib (ICP-723), our rapidly maturing early-stage pipeline, including the cornerstone therapy ICP189 and ICP-B05, will enable us to establish a solid footprint in the field of solid tumor treatment.

Autoimmune Diseases
Developing B-cell and T-cell Pathways in Autoimmune Diseases

We have fortified our powerful discovery engine in the global frontier targets for the development of autoimmune therapeutics through B-cell and T-cell pathways for the purpose of providing the first-in-class and/or best-in-class treatments to the massive unmet clinical needs with a promising market potential in global and/or regional markets.

Building a Leading Franchise in Hemato-oncology

With orelabrutinib serving as our backbone therapy and a key component of our extensive pipeline in hemato-oncology – including tafasitamab, ICP-B02, ICP-490, ICP-248, potential future developments from internal and external sources – our goal is to address various segments, such as non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and leukemia, utilizing both single and combination therapies, with the aim to become a leading player in hemato-oncology both in China and worldwide.